Seeking Alpha

Karl Strpklin's  Instablog

Karl Strpklin
Send Message
  • MHAN, PWRM, VSH, TA - Stock Report! Nov 11th 1 comment
    Nov 11, 2010 1:32 PM

    money 1


    PWRM, Power 3 Medical Products Inc., PWRM.OB has signed a definitive agreement recently to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed sometime by the end of this year, 2010.

    Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally.

    Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

    Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.

    Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials.

    These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

    Power3 Medical Product's Website


    Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced recently that it has been awarded $244,279 in funding under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) credit program. The Company has received this funding for its lead product candidate AST-726 for the treatment of vitamin B12 deficiency.

    Manhattan Pharmaceuticals is a specialty healthcare product company focused on the development and commercialization of innovative treatments for underserved patient populations.


    Vishay Intertechnology, Inc. (NYSE:VSH) recently announced the closing of its offering of $275 million principal amount of 2.25% convertible senior debentures due 2040. The debentures were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

    Vishay Intertechnology, Inc. manufactures and supplies semiconductors and passive electronic components in the United States, Europe, and Asia.


    TravelCenters of America LLC (NYSE:TA) recently announced financial results for the three and nine months ended September 30, 2010.

    In addition to the historical financial results prepared in accordance with generally accepted accounting principles, or GAAP, and presented in this press release, TA is furnishing supplemental data that it believes may help investors better understand TA’s business.

    TA’s travel centers operate under the “TravelCenters of America”, “TA” and “Petro” brand names and offer diesel and gasoline fueling services, restaurants, truck repair facilities, stores and other services. T




    Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).

    Sign Up for our FREE Daily Stock Newsletter

Back To Karl Strpklin's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • deeppocketsgolf
    , contributor
    Comments (114) | Send Message
    Manhattan Pharmaceuticals: MHAN;[Mentioned Above]


    Market Cap; 1.4M


    Last: .011;




    Per Share Equity Statement; Development Stage Since '01;
    Change in Equity: (5.36M) @ .0108;


    Report Category, Per Report, Price: , Metric. , Weight. , Combined Trading Metric ,Year / Designation, Weight Adj Price.


    20. Common Stock Amount: 120.966K, Report 10-K SE Statement:, 0.011 , 12 , 1.38 , 16 ,Price1, 0.015


    21. Additional Paid in Capital: 55.808M, Report 10-K SE Statement:, 0.011 , 0.03 , 0.98 , 0.02 ,Price2, 0.0107


    22.Accum Deficit Development Stage '01 to '10: (61.310M), Report 10-K SE Statement:, 0.011 , (0.02) , 1.47 , (0.03) ,Price3, 0.016


    23. Other Equity: 16K, Report 10-K SE Statement:, 0.011 , 89 , 1.10 , 98 ,Price4, 0.012


    24. Misc Equity: 8K, Report 10-K SE Statement:, 0.011 , 160 , 1.01 , 162 , LowPrice, (0.011)


    Per Share Equity Statement, Equity: $(5.36M) Sum Trading At: ,Primary Metric(s) per Statement: 260.19 ,Metric Weighted per Price Range / Change, 6.404 ,Combined; Weight Adj Trade Metric, 275.8445, for (0.269)M Market Cap; for (0.0021) off adjusted level price of 1.29 Cents; Weighted over last 12.00 DAYS;


    Estimate of Forward Activity:


    Net$$MM Accumulated Deficit Development Stage Since '01: (61.310)
    MinRetGrowth: 0.03
    MinRetInv: 0.05
    Weighted Cost of Capital: 91.02%
    Estimated Local Continuing Value in $$M: (23.4)
    Estimated Factor NOT LOCAL in $$M: 0.301636
    Estimated ContinuingValue: Sales $$MM: (7.043673)
    Estimated NOT LOCAL Price : 0.0404
    (0.05427), Factor Forward.
    (0.74), Not Local Price To.
    (6.517M) , Avg R&D / Net Loss Expense Since '01;


    Recent Monthly Share Volume: 758K
    YTD Volume:10M


    2007:40 Cents on 1.8M Shares being traded;




    Do not own Shares; Review the Company;
    16 May 2011, 06:30 PM Reply Like
Full index of posts »
Latest Followers

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.